Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

laboratoire innotech international - neomycinum + polymyxinum b + nystatinum - capsule moi vaginale - 35000 ui+35000 ui+100000 ui

Uniunea Europeană - română - EMA (European Medicines Agency)

seqirus netherlands b.v. - a/darwin/6/2021(h3n2)-like strain (a/darwin/11/2021, wild type) / a/wisconsin/67/2022 (h1n1)pdm09-like strain (a/georgia/12/2022 cvr-167) / b/austria/1359417/2021-like strain (b/singapore/wuh4618/2021) / b/phuket/3073/2013-like virus (b/singapore/inftt-16-0610/2016, wild type) - gripa, umană - gripa, cu virus inactivat, split virusului sau antigenului de suprafață al - prophylaxis of influenza in adults and children from 2 years of age. flucelvax tetra ar trebui să fie utilizate în conformitate cu recomandările oficiale.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

innothera chouzy - franta - combinatii (neomicinum+polimixinum+nystatinum) - caps. moi vag. - antiinfectioase (excl. combinatii cu corticosteroizi) antibiotice

Republica Moldova - română - ANSA (Agenţia Naţională pentru Siguranţa Alimentelor)

s.c vanelli srl, romania - ca, - pulbere

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

apl swift services (malta) limited - malta - moxifloxacinum - compr. film. - 400mg - chinolone antibacteriene fluorochinolone

Uniunea Europeană - română - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agenți antineoplazici - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Uniunea Europeană - română - EMA (European Medicines Agency)

pinax pharma gmbh - ioflupan (123i) - radionuclide imaging; dementia; movement disorders - produse radiofarmaceutice de diagnosticare - acest medicament este destinat exclusiv diagnosticului. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. la pacienții adulți, pentru a diferenția demența cu corpi lewy de boala alzheimer.  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

laboratoire innotech international - neomycinum + polymyxinum b + nystatinum - capsule moi vaginale - 35000 ui/35000 ui/100000 ui

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

laboratoire innotech international - neomycinum + polymyxinum b + nystatinum - capsule moi vaginale - 35000 ui/35000 ui/100000 ui

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

farmalider s.a. - spania - ibuprofenum - susp. orala - 40mg/ml - antiinflamatoare si antireumatice nesteroidiene derivati de acid propionic